首页> 外文期刊>Gastrointestinal Endoscopy >Randomized sham-controlled trials in endoscopy: a systematic review and meta-analysis of adverse events
【24h】

Randomized sham-controlled trials in endoscopy: a systematic review and meta-analysis of adverse events

机译:内窥镜检查中随机假手术试验:对不良事件的系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Aims Sham procedures in endoscopy are used with the intention of controlling for placebo response, potentially allowing more precise evaluation of treatment effect. Nevertheless, this type of study may impose significant risk without potential benefit for those in the sham group. The aim of the current study was to systematically review and analyze the endoscopic literature to assess the safety of sham controls. Methods MEDLINE and Embase databases were searched for endoscopic sham procedures for all dates to July 2017. Only randomized controlled trials comparing an endoscopic therapy with a sham were included. Primary outcome was adverse events (AEs) categorized as mild, moderate, or severe. Results were combined using a random-effects model. Heterogeneity was assessed with the I 2 statistic, and publication bias was assessed with the Egger test and funnel plots. Results Data were extracted from 34 publications (1987-2017; 100% full text), with a total of 2492 procedures (1355 treatment/1137 sham). Sham procedures involved upper endoscopy (31 studies) and ERCP (3 studies). Treatment arms included procedures with the following indications: weight loss (38.2%), GI bleeding (26.5%), GERD (20.6%), sphincter of Oddi dysfunction (8.8%), and dysphagia (6.2%). Overall percentage of severe adverse events (SAEs) in the sham group was 1.7% (19/1137). Of these, the most common SAEs in the sham groups were need for surgery/intensive care unit stay (35.3%), post-ERCP pancreatitis (23.5%), and perforation (11.8%). There was no significant difference in the odds of developing an SAE between the treatment group and the sham group (odds ratio, 1.3; 95% confidence interval [CI], 0.7-2.3). The pooled additional risk incurred from being initially randomized to the sham arm and then receiving a cross-over intervention was significant (RR, 1.33; 95% CI, 1.14-1.56; P Conclusion The frequency of AEs in endoscopic sham procedures is substantial, and patients are subjected to considerable morbidity. These results raise a serious ethical dilemma regarding the use of sham-controlled trials.
机译:背景和目标内窥镜检查中的假手术用于控制安慰剂响应的意图,可能允许更精确地评​​估治疗效果。然而,这种类型的研究可能会对假小组中的潜在利益施加重大风险。目前研究的目的是系统地审查和分析内窥镜文献,以评估假对照的安全性。方法搜索MEDLINE和EMBASE数据库,用于所有日期的内窥镜假手术到2017年7月。只有随机对照试验,将内窥镜疗法与假的内窥镜治疗进行了比较。主要结果是不良事件(AES)分类为轻度,中度或严重。使用随机效应模型合并结果。用I 2统计评估异质性,并通过Egger测试和漏斗图评估出版物偏差。结果数据从34个出版物(1987-2017; 100%全文)中提取,共有2492个程序(1355治疗/ 1137假)。假手术涉及上内窥镜检查(31项研究)和ERCP(3研究)。治疗武器包括以下适应症的程序:减肥(38.2%),GI出血(26.5%),GERD(20.6%),Oddi功能障碍(8.8%)和吞咽括号(6.2%)。假手术组中严重不良事件(SAE)的总体百分比为1.7%(19/1137)。其中,假手术组中最常见的SAES需要手术/重症监护室住宿(35.3%),ERCP后胰腺炎(23.5%)和穿孔(11.8%)。在治疗组和假组合之间发展SAE的几率没有显着差异(赔率比,1.3; 95%置信区间[CI],0.7-2.3)。从最初被随机化到假手臂然后接受交叉干预的汇集额外风险很大(RR,1.33; 95%CI,1.14-1.56; P结论内窥镜假手术中AES的频率很大,而且患者受到相当大的发病率。这些结果提高了关于假手法试验的严重伦理困境。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号